Cyrille J. Cohen

6.4k total citations · 2 hit papers
64 papers, 4.6k citations indexed

About

Cyrille J. Cohen is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Cyrille J. Cohen has authored 64 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 44 papers in Immunology and 16 papers in Molecular Biology. Recurrent topics in Cyrille J. Cohen's work include CAR-T cell therapy research (44 papers), Immunotherapy and Immune Responses (32 papers) and Immune Cell Function and Interaction (21 papers). Cyrille J. Cohen is often cited by papers focused on CAR-T cell therapy research (44 papers), Immunotherapy and Immune Responses (32 papers) and Immune Cell Function and Interaction (21 papers). Cyrille J. Cohen collaborates with scholars based in Israel, United States and Germany. Cyrille J. Cohen's co-authors include Steven A. Rosenberg, Richard A. Morgan, Zhili Zheng, Yangbing Zhao, Paul F. Robbins, Miryam Horovitz‐Fried, Katerina Shamalov, Mona El‐Gamil, Yong F. Li and Noa Dagan and has published in prestigious journals such as Nature, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Cyrille J. Cohen

64 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

2021 558 citations Noam Barda, Noa Dagan et al. The Lancet profile →
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

2019 546 citations Vasyl Eisenberg, Cyrille J. Cohen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cyrille J. Cohen Israel	30	2.9k	2.6k	1.2k	986	553	64	4.6k
Richard A. Morgan United States	44	4.8k 1.7×	2.8k 1.1×	2.7k 2.2×	2.5k 2.5×	877 1.6×	112	7.4k
Bernard A. Fox United States	48	4.4k 1.5×	4.4k 1.7×	2.2k 1.8×	954 1.0×	262 0.5×	200	7.6k
Mustafa Diken Germany	34	2.0k 0.7×	3.0k 1.2×	2.9k 2.3×	628 0.6×	448 0.8×	93	5.4k
Karine Breckpot Belgium	54	3.2k 1.1×	4.5k 1.7×	3.4k 2.8×	1.1k 1.1×	637 1.2×	170	7.6k
Karen S. Anderson United States	40	1.6k 0.6×	1.9k 0.7×	2.2k 1.8×	331 0.3×	404 0.7×	134	4.9k
Thorbald van Hall Netherlands	47	4.1k 1.4×	6.1k 2.4×	2.5k 2.0×	480 0.5×	500 0.9×	127	8.1k
Francisco J. Cueto Spain	14	1.5k 0.5×	2.4k 0.9×	921 0.8×	115 0.1×	395 0.7×	22	3.3k
Yoram Reiter Israel	41	1.3k 0.5×	3.0k 1.1×	1.5k 1.2×	204 0.2×	180 0.3×	107	4.4k
Heleen Dewitte Belgium	22	412 0.1×	785 0.3×	1.2k 1.0×	235 0.2×	808 1.5×	34	2.5k
Timothy M. Clay United States	41	2.2k 0.8×	3.2k 1.2×	2.6k 2.1×	796 0.8×	440 0.8×	97	5.9k

Countries citing papers authored by Cyrille J. Cohen

Since Specialization

Citations

This map shows the geographic impact of Cyrille J. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cyrille J. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cyrille J. Cohen more than expected).

Fields of papers citing papers by Cyrille J. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cyrille J. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cyrille J. Cohen. The network helps show where Cyrille J. Cohen may publish in the future.

Co-authorship network of co-authors of Cyrille J. Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Cyrille J. Cohen. A scholar is included among the top collaborators of Cyrille J. Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cyrille J. Cohen. Cyrille J. Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eisenberg, Vasyl, Iris Kamer, Jair Bar, et al.. (2024). Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells. Cancer Immunology Research. 12(10). 1380–1391. 3 indexed citations

Cohen, Cyrille J., et al.. (2024). Targeting TGFβ with chimeric switch receptor and secreted trap to improve T cells anti-tumor activity. Frontiers in Immunology. 15. 1460266–1460266. 1 indexed citations

Kfir‐Erenfeld, Shlomit, Batia Avni, Sigal Grisariu, et al.. (2023). Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma. Blood. 142(Supplement 1). 4852–4852. 1 indexed citations

Kfir‐Erenfeld, Shlomit, Sigal Grisariu, Batia Avni, et al.. (2022). Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clinical Cancer Research. 28(23). 5156–5166. 21 indexed citations

Shamalov, Katerina, et al.. (2022). Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. PubMed. 113. 253–294. 7 indexed citations

Betzer, Oshra, Yue Gao, Menachem Motiei, et al.. (2022). Multifunctional nanoprobe for real-time in vivo monitoring of T cell activation. Nanomedicine Nanotechnology Biology and Medicine. 46. 102596–102596. 2 indexed citations

Barda, Noam, Noa Dagan, Cyrille J. Cohen, et al.. (2021). Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. The Lancet. 398(10316). 2093–2100. 558 indexed citations breakdown →

Alon, Danny, et al.. (2021). Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide. Frontiers in Medicine. 8. 675963–675963. 4 indexed citations

Eisenberg, Vasyl, et al.. (2019). T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer. Advanced Drug Delivery Reviews. 141. 23–40. 23 indexed citations

10.

Meir, Rinat, Katerina Shamalov, Cyrille J. Cohen, & Rachela Popovtzer. (2019). Predicting treatment outcome and enhancing immunotherapy with anti-PDL1 gold nanoparticles. 1. 3–3. 1 indexed citations

11.

Eisenberg, Vasyl, et al.. (2019). A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function. Journal for ImmunoTherapy of Cancer. 7(1). 243–243. 62 indexed citations

12.

Deniger, Drew C., Anna Pasetto, Eric Tran, et al.. (2016). Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. Molecular Therapy. 24(6). 1078–1089. 54 indexed citations

13.

Prickett, Todd D., Jessica S. Crystal, Cyrille J. Cohen, et al.. (2016). Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunology Research. 4(8). 669–678. 88 indexed citations

14.

Horovitz‐Fried, Miryam, et al.. (2013). Enhanced antitumor activity mediated by human 4‐1BB‐engineered T cells. International Journal of Cancer. 133(12). 2903–2913. 28 indexed citations

15.

Horovitz‐Fried, Miryam, et al.. (2012). Incorporation of Transmembrane Hydrophobic Mutations in the TCR Enhance Its Surface Expression and T Cell Functional Avidity. The Journal of Immunology. 188(11). 5538–5546. 61 indexed citations

16.

Horovitz‐Fried, Miryam, et al.. (2010). Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition. The Journal of Immunology. 184(11). 6232–6241. 64 indexed citations

17.

Cohen, Cyrille J., Yong F. Li, Mona El‐Gamil, et al.. (2007). Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide Bond. Cancer Research. 67(8). 3898–3903. 276 indexed citations

18.

Johnson, Laura A., Bianca Heemskerk, Daniel J. Powell, et al.. (2006). Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes. The Journal of Immunology. 177(9). 6548–6559. 240 indexed citations

19.

Cohen, Cyrille J., Zhili Zheng, Yangbing Zhao, et al.. (2005). Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR. The Journal of Immunology. 175(9). 5799–5808. 94 indexed citations

20.

Cohen, Cyrille J., James Hellinger, John Day, et al.. (1996). Lack of Effect of Cimetidine on Lymphocyte Subsets in Patients Infected with Human Immunodeficiency Virus Type 1. Clinical Infectious Diseases. 23(5). 1049–1054. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact